-- 
Biogen Idec, Elan Say FDA Extends Date to Decide Tysabri Change

-- B y   P h i l   S e r a f i n o
-- 
2011-10-20T12:35:05Z

-- http://www.bloomberg.com/news/2011-10-20/biogen-idec-elan-say-fda-extends-date-to-decide-tysabri-change.html
Biogen Idec and Elan Corp. said the
U.S.  Food and Drug Administration  extended the deadline for its
review of a proposed change to the prescribing information for
the multiple sclerosis drug Tysabri.  To contact the editor responsible for this story:
Phil Serafino at 
 pserafino@bloomberg.net  